Q-omics provides the consensus-scored VARS2 profile across patient tissues and cancer cell-line models. VARS2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, VARS2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, VARS2 RNA expression shows 19,402 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, and ACC as cancer lineages where VARS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VARS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VARS2 survival associations across molecular data types. VARS2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VARS2 RNA expression–survival associations across cancer types. High VARS2 expression shows unfavorable associations in COAD, UVM, THCA and ACC, but favorable associations in KIRP and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for VARS2 RNA expression.
This table summarizes VARS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VARS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VARS2 shows higher tumor expression in COAD, BLCA, KIRC, LUSC, LUAD and LIHC. The COAD box plot shows higher VARS2 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with VARS2 in patient tissues and cancer cell lines. In patient samples, VARS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VARS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
